A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Asia

A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine + amodiaquine (AL+AQ) and artesunate- mefloquine+piperaquine (AS-MQ+PPQ) with the ACTs artemether-lumefantrine + placebo (AL+PBO) and artesunate- mefloquine + placebo (AS-MQ+PBO) (with single-low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria to assess and compare their efficacy, safety, tolerability.

开始日期2021-06-30

申办/合作机构

University of Oxford

NCT04847661

/ Completed临床2/3期IIT

Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial

The aim of this study is to evaluate the efficacy and safety of Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed. This study is an open-label, randomized, placebo controlled trial.
A total of 1500 household contacts of COVID-19 confirmed cases who will attend triaging clinic of 5 Egyptian university centers (Helwan university hospital, Ain Shams university hospital, Assiut University Hospital, Fayoum university hospital and Tanta university hospital). The household contacts of COVID-19 confirmed subjects with a decision for home-isolation will be recruited to participate into this study. The recruited subjects from each center will be randomly assigned (locally in that center) into 2 groups (750 volunteer in each group). The 1st group will receive Mefloquine (1100-1650 mg according to body weight), orally, while the other group will receive the same number of placebo tablets (control group). Previous infection will be excluded for all recruited subjects by testing for the presence of anti-bodies against COVID-19 to exclude previous infection. Subjects who are tested negative will be allocated into one of the 2 study groups after randomization, and treatment will be started immediately (either mefloquine or placebo). In addition, a nasopharyngeal swap will be taken from each recruited subject and tested by PCR for COVID-19 to exclude current infection. After having the PCR results, positive cases will be analyzed separately to test for the disease severity.
Neurological and cardiac assessment will be done for all volunteers before recruitment to exclude the presence of any contraindication for Mefloquine intake. Both groups will be followed up clinically to detect any symptom or sign of COVID-19 infection for 2 weeks (during the period of home isolation). Nasopharyngeal swap with PCR for COVID-19 will be done for all included subjects at the end of the follow-up period (14 days), or at the appearance of symptoms or signs suggesting COVID-19 infection.
Primary end points of the study are either:
End of follow up period (2 weeks)
Confirmed diagnosis of COVID-19 infection during the study time Initial severity assessment of COVID-19 infection will be done in all infected subjects in both groups to compare severity, in addition to following up of the fate of the infected subjects.

开始日期2021-03-28

申办/合作机构

Helwan University

[+4]

NCT04347031

/ Completed临床2/3期IIT

An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19

Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.

开始日期2020-04-08

申办/合作机构-

100 项与盐酸甲氟喹相关的临床结果

登录后查看更多信息

100 项与盐酸甲氟喹相关的转化医学

登录后查看更多信息

100 项与盐酸甲氟喹相关的专利（医药）

登录后查看更多信息

3,198

项与盐酸甲氟喹相关的文献（医药）

2025-03-01·Journal of Molecular Graphics and Modelling

Brussonol and komaroviquinone as inhibitors of the SARS-CoV-2 Omicron BA.2 variant spike protein: A molecular docking, molecular dynamics, and quantum biochemistry approach

Article

作者: Santos, Samuel J M ; Valentini, Antoninho

Since late 2019, humanity has faced the challenges posed by the COVID-19 pandemic, caused by the SARS-CoV-2 virus. The continuous evolution of SARS-CoV-2 has led to the emergence of multiple Variants of Concern (VOCs) and Variants of Interest (VOIs), posing significant risks to global health. SARS-CoV-2 infects host cells via the angiotensin-converting enzyme 2 (ACE2) receptors, facilitated by the spike (S) protein. Icetexane diterpenes, including brussonol and komaroviquinone, exhibit notable anti-inflammatory, antibacterial, antiviral, antiproliferative, and anticancer properties. Recent research has explored their potential as inhibitors of the SARS-CoV-2 3Clpro protease, showing promising efficacy comparable to Nirmatrelvir. This study investigates brussonol and komaroviquinone as potential inhibitors of the SARS-CoV-2 Omicron BA.2 variant spike protein using molecular docking, molecular dynamics simulations, and quantum biochemistry approaches. The stability and interaction energies of brussonol, komaroviquinone, and mefloquine with the SARS-CoV-2 Omicron BA.2 variant spike protein were evaluated. RMSD analysis demonstrated that komaroviquinone and mefloquine maintain more stable binding poses with the spike protein compared to various NAGs and glycans. Electrostatic potential maps revealed significant interactions with ASN603, a critical residue for ligand binding efficacy. Furthermore, this study addresses a gap in current research, as no studies were found that simulate the trimer of the SARS-CoV-2 BA.2 variant spike protein. Most existing studies focus on the monomer and often exclude the NAGs and glycans. This research underscores the importance of maintaining the NAGs and glycans in the trimer simulations, providing a more accurate representation of the protein's structure and its interactions with ligands. The findings indicate that both komaroviquinone and brussonol exhibit higher binding affinities compared to mefloquine. This study provides valuable insights into the molecular interactions of these compounds, highlighting their potential for further development as antiviral agents against SARS-CoV-2.

2025-01-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Chiral separation and spectroscopic characterization of mefloquine analogues

Article

作者: Dobšíková, K. ; Dobšíková, K ; Setnička, V ; Kohout, M ; Setnička, V. ; Kohout, M.

Mefloquine, a widely used antimalarial agent, has spurred ongoing research into the development of derivatives with enhanced efficacy and reduced side effects. In this investigation, we synthesized two compounds containing N-allyl or N-tert-butylacetamid groups. A chiral liquid chromatography with polysaccharide chiral stationary phase was utilized to separate the enantiomers of both derivatives. We employed spectroscopic chiroptical and non-polarizable methods such as electronic and vibrational circular dichroism, infrared absorption and ultraviolet spectroscopies. Combined with density functional theory calculations, the stable conformers were found in solution and their spectra were subsequently simulated. We elucidated the three-dimensional structure of the enantiomerically pure compounds and assigned the absolute configuration of all prepared derivatives using both experimental and simulated spectra.

2024-11-23·Cureus

Synergistic Effects of Anti-echinococcosis Drug Candidates Combined With Atovaquone in Culture Assays and Mice With Primary Infections of Echinococcus multilocularis

Article

作者: Kouguchi, Hirokazu ; Nakao, Ryo ; Koyano, Tomohito ; Hidaka, Masahito ; Matsuyama, Hiroyuki ; Nonaka, Nariaki ; Enkai, Shigehiro ; Hayashi, Naoki ; Yagi, Kinpei

Background Alveolar echinococcosis (AE) is a fatal zoonotic disease distributed mainly in the Northern Hemisphere. At present, its curative treatment relies on surgery, and the development of effective drugs is needed. We previously demonstrated the anti-echinococcal effect of atovaquone (ATV) as a mitochondrial complex III inhibitor in both in vitro and in vivo experiments. However, the anti-echinococcal effect of ATV in vivo was limited, since ATV inhibits only aerobic respiration. In this study, we investigated whether ATV exhibits a synergistic effect when used in combination with other anti-echinococcal drug candidates, including mefloquine (MF), 3-bromopyruvic acid (3BP), crocin, and verapamil (Ver), thereby enhancing their antiparasitic effectiveness. Methods The synergistic effect of anti-echinococcal drug candidates with ATV was examined in culture experiments with Echinococcus multilocularis protoscoleces. Based on the results of these culture experiments, ATV and 3BP were individually and in combination orally administered to BALB/c mice infected with E. multilocularis (dose of 300 eggs). Each drug treatment was started three days prior to infection and continued until day 28 after egg administration, and the number of cysts located in the liver was evaluated (Experiment A). The anti-echinococcal effectiveness of the combination of ATV and 3BP was also evaluated by treating mice with E. multilocularis primary infection for eight weeks (Experiment B) and comparing the effects on cyst growth to those of albendazole (ABZ). Results Culture experiments with E. multilocularis protoscoleces showed that the combined treatments of ATV with 3BP, MF, and Ver were more effective at parasite elimination under both aerobic and anaerobic conditions than the single drug treatments. Crocin was ineffective in the culture assay. In Experiment A, the number of cysts was significantly reduced only in the groups treated with ABZ alone (median 48.0, interquartile range 36.3-58.0) and the combination of ATV and 3BP (median 54.5, interquartile range 46.5-62.8) compared to the control (median 90.0, interquartile range 67.0-100.5). MF and Ver did not exhibit significant in vivo effects on their own. In Experiment B, the group treated with ATV + 3BP showed a similar anti-echinococcal effect as the group treated with ABZ alone. Conclusion In the culture assay, ATV in combination with 3BP, MF, and Ver showed a synergistic effect, enhancing the anti-echinococcal effect under both aerobic and anaerobic conditions. In mice experimentally treated with primary hydatid cysts, co-administration of ATV and 3BP showed a significant preventive effect against infection and demonstrated therapeutic efficacy comparable to that of ABZ. These findings are anticipated to contribute to the development of more effective therapeutic agents for AE.

项与盐酸甲氟喹相关的新闻（医药）

2024-10-29

·生物探索

Cell | 群落行为如何影响药物-肠菌作用

引言药物会影响人体肠道微生物组的组成和功能【1-2】。研究表明，数百种药物（如抗生素）会直接抑制肠道共生菌的生长【3-4】。反之，肠道微生物对药物的代谢或吸收也会影响药物的生物利用度和药效【1,5】。近年来，随着肠道微生物培养技术的进步，越来越多的研究开始大规模探索不同药物与肠道微生物之间的相互作用。然而，对于“单一物种与药物的相互作用在群落状态下是否会受到影响”这一问题，人们仍知之甚少。近日，欧洲分子生物学实验室（EMBL）Athanasios Typas、Peer Bork、Michael Zimmermann和Kiran R. Patil团队共同在Cell杂志上发表了题为Emergence of community behaviors in the gut microbiota upon drug treatment的文章。该研究比较了30种药物对含有32种菌的人工合成群落的影响以及对每个群落成员的单独影响，发现当药物作用于群落时，微生物成员的相互作用会导致群落行为的涌现，从而改变微生物成员对药物的敏感性。首先，作者构建了一个由32种代表性肠道微生物（来自6个门、26个属）组成的人工合成群落，并根据其之前的研究【3】筛选出了30种具有代表性的药物（能抑制不同微生物的生长且涵盖多个不治疗领域），以测试肠道微生物和药物之间的相互作用。作者将不同浓度的药物加入到人工合成群落或单一物种培养物中，并比较其对不同物种生长的影响。比较结果可分为3种：（1）不存在差异，在群落和单一培养条件下，微生物生长受到类似影响或均不受影响；（2）交叉敏感化（cross-sensitization），微生物在单独生长时不受到药物影响（耐药），但在群落状态下受到抑制、丰度降低；（3）交叉保护（cross-protection），微生物在单独生长时受到药物的抑制作用（对药物敏感），但在群落状态下生长正常。结果显示，在群落环境中，大部分（74%）药物-微生物成员之间的相互作用不变，但每种药物都会引发群落行为，共有26%的药物-微生物成员之间的相互发生了变化。当仅考虑对药物敏感的物种时，发生交叉保护作用的测试占全部测试的47%；当仅考虑耐药的物种时，发生交叉敏感化的测试占全部测试的8%。上述结果提示在进行药物治疗后，人体肠道微生物组会出现许多交叉保护或交叉敏感化事件，且由于不同个体的肠道微生物组不同，上述群落事件可能会因人而异。比较3种药物浓度的结果，作者发现，随着药物浓度的增加，群落中受到保护的物种减少，敏感物种增加。这表明在低药物浓度下，群落可以抵抗干扰，而在高浓度下，群落会发生崩溃，不仅无法保护敏感物种，且还有可能由于微生物之间的相互作用导致原本具有抗性的物种生长受到抑制。微生物对药物的代谢转化或吸收积累作用可能是引发交叉保护或交叉敏感化的机制。由于大部分群落行为属于交叉保护作用，因此作者进一步探究了交叉保护作用背后的机制。为此，作者使用LC-MS测量了药物浓度随时间的变化，并通过比较整个群落（包含上清液和细菌）样本与上清液样本来区分生物转化作用和生物积累作用。结果显示，药物生物转化和生物积累在一定程度上可以解释群落产生的交叉保护现象。例如，质子泵抑制剂兰索拉唑的衰变会因微生物群落而加快；抗寄生虫药物氯硝柳胺会被微生物群落快速代谢；抗疟疾药物甲氟喹既存在生物积累作用，也存在生物转化作用。并且作者发现，在该研究的大多数情况下，药物生物转化会产生无害或毒性较小的物质。接着作者进一步聚焦了3种药物芳香硝基化合物——抗寄生虫药物氯硝柳胺和硝呋莫司以及治疗帕金森病的药物恩他卡朋。结果显示，不同物种对同一药物的耐药机制不同，从而会对群落产生不同影响。如Roseburia intestinalis、Coprococcus comes和具核梭杆菌能够还原氯硝柳胺，使其失去活性，大幅降低群落环境中该药物的浓度，从而保护其他敏感物种。而大肠杆菌无法降解该药物，但可在其胞内积累，因此难以为其他敏感物种提供保护作用。利用上述结果，作者发现其可以设计出更能抵抗药物治疗的群落，即通过向对氯硝柳胺敏感的小群落中加入C. comes可以有效恢复群落的生长。最后作者鉴定确定了与氯硝柳胺交叉保护作用相关的硝基还原酶（可还原芳香硝基化合物），其重点研究了两个物种：（1）R. intestinalis，对氯硝柳胺具有中等抗性且能够为其他敏感物种提供保护作用，编码2种假定的硝基还原酶；（2）Phocaeicola vulgatus，对氯硝柳胺敏感，但编码了7种假定的硝基还原酶。结果显示，过表达2种R. intestinalis硝基还原酶中的任何一种，都会使P. vulgatus对氯硝柳胺更加耐受。然而，有趣的是过表达P. vulgatus中的2种硝基还原酶也会使其变得更耐受。进一步检测蛋白质浓度发现，尽管这2种酶能够还原氯硝柳胺，但是其在P. vulgatus中的表达浓度很低，而2种R. intestinalis硝基还原酶的表达量都很高。上述结果表明，尽管很多物种都可能具有药物生物转化能力，但是在药物治疗后并不一定会大量表达相关的酶。模式图（Credit: Cell）综上，该研究表明大多数药物-肠道细菌的相互作用在群落中保持不变，但是交叉保护作用和交叉敏感化几乎会发生在每种药物上。该研究有助于建立更精确的药物-肠道微生物预测模型，预测肠道微生物群落对药物的响应，并进一步强调了在药物设计过程中需要考虑肠道微生物因素。参考文献 1. Zimmermann, M., Patil, K.R., Typas, A., and Maier, L. (2021). Towards a mechanistic understanding of reciprocal drug–microbiome interactions. Mol. Syst. Biol. 17, e10116. https://doi-org.libproxy1.nus.edu.sg/10.15252/MSB.202010116. 2. Maier, L., and Typas, A. (2017). Systematically investigating the impact of medication on the gut microbiome. Curr. Opin. Microbiol. 39, 128–135. https://doi-org.libproxy1.nus.edu.sg/10.1016/J.MIB.2017.11.001. 3. Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E.E., Brochado, A.R., Fernandez, K.C., Dose, H., Mori, H., et al. (2018). Exten- sive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628. https://doi-org.libproxy1.nus.edu.sg/10.1038/nature25979. 4. Maier, L., Goemans, C.V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Mu ̈ ller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., et al. (2021). Unravelling the collateral damage of antibiotics on gut bacteria. Nature 599, 120–124. https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-021-03986-2. 5. Klu ̈ nemann, M., Andrejev, S., Blasche, S., Mateus, A., Phapale, P., Deven- dran, S., Vappiani, J., Simon, B., Scott, T.A., Kafkia, E., et al. (2021). Bio- accumulation of therapeutic drugs by human gut bacteria. Nature 7877, 533–538. https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-021-03891-8. https://doi-org.libproxy1.nus.edu.sg/10.1016/j.cell.2024.08.037 责编|探索君排版|探索君来源|BioArt End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell综述

微生物疗法

2024-03-02

·生物探索

Nat Commun | 厦门大学李剑课题组发现疟原虫抗药的新机制

引言疟疾是由疟原虫感染引起的传染性寄生虫病，全球每年有超过2.4亿人感染，造成~60万人死亡。当前，恶性疟原虫几乎对所有类型的抗疟药包括青蒿素及青蒿素类复方药均产生了不同程度的抗性。抗药性疟原虫的出现、演化及蔓延是疟疾防治和根除的主要难题。跨膜转运蛋白MDR1是哺乳类P-gp蛋白的同源物，早期的研究显示MDR1定位于疟原虫的消化泡（digestive vacuole, DV）泡膜。该蛋白可转运不同类型的抗疟药/引起不同的药敏反应而受到耐药性研究领域的广泛关注。然而，调控MDR1亚细胞定位及抗药性发生的机制一直是个谜。2024年2月27日，厦门大学生命科学学院李剑课题组在Nature Communications 发表题为“Deaggregation of mutant Plasmodium yoelii de-ubiquitinase UBP1 alters MDR1 localization to confer multidrug resistance”的研究论文，该研究揭示疟原虫去泛素化酶UBP1突变体通过调节MDR1的泛素化和改变其细胞定位，介导MDR1对多种抗疟药的外排，引起疟原虫产生多重抗药性。研究人员首先通过甲氟喹（mefloquine）筛选、构建遗传杂交和遗传定位，发现约氏疟原虫的UBP1编码基因与抗药表型相连锁，并新发现两个独特的与抗药性相关的点突变I1560N和P2874T（均为疏水性氨基酸突变为亲水性氨基酸），突变位点分别位于CCR和UCH功能结构域。接着研究人员应用基因编辑技术对敏感性虫株（IP单倍型）和抗性虫株（NT单倍型）的ubp1进行一系列单点和双点等位替换，正向及反向替换的药敏测试结果证明在两个位点同时突变的情形下疟原虫具有多重抗药性，即突变体对甲氟喹、苯芴醇（lumefantrine）及哌喹（piperaquine）等抗疟药（常用作青蒿素类复方的伴侣药物）均产生了抗性。深入的表型分析阐明双点突变不仅损坏UBP1去泛素化酶的生理功能，而且显著降低原虫率和消化泡中疟色素的生成。UBP1蛋白含有3100多个氨基酸，分析显示该蛋白序列存在高度的固有无序域（intrinsically disordered region, IDR），提示其可通过相分离形成无膜细胞器或凝聚体。质谱鉴定和免疫印迹研究表明，MDR1是UBP1酶促作用的底物蛋白。机制分析发现，野生型UBP1形成具功能性的点状凝聚体对MDR1进行去泛素化，脱泛素化的MDR1定位于消化泡膜；而突变型UBP1由于IP→NT突变破坏了凝聚体的形成及酶活性，导致MDR1泛素化水平升高，造成MDR1易位至细胞质膜，此时MDR1可将抗疟药泵出胞外以降低胞内的药物浓度，致使疟原虫获得抗性。最后，研究者使用P-gp抑制剂他立喹达（tariquidar）与甲氟喹等进行联合用药，发现组合用药可显著杀灭抗性疟原虫。模式图（Credit: Nature Communications）该研究发现并解析了一种新的疟原虫抗药机制：UBP1位点突变→凝聚体及酶活性受损→泛素化水平升高致使MDR1从消化泡膜易位至细胞质膜→药物外排→抗药性产生。研究结论对于抗药性的监测，抗疟药研发和联合用药有重要的指导意义。原文链接https://www-nature-com.libproxy1.nus.edu.sg/articles/s41467-024-46006-3责编|探索君排版|探索君文章来源|“iNature”End往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文Nature | 破除传统：为何我们需要重新思考肿瘤的命名方式热文Nature | 2024年值得关注的七项技术热文Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文Nature | 癌症与神经系统的致命舞蹈

2023-01-26

·PRNewswire

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

--Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses --Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of ASC10 and its derivatives, and their uses to treat multiple virus infections HANGZHOU and SHAOXING, China, Jan. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of ASC10 for monkeypox indication. ASC10 is an oral double prodrug. After oral administration, both ASC10 and single prodrug molnupiravir are rapidly and completely converted in vivo into the same active metabolite ASC10-A, also known as β-D-N4-hydroxycytidine (NHC) or EIDD-1931. Preclinical studies show that ASC10-A has broad spectrum antiviral activities including potent activities against both monkeypox and SARS-CoV-2 viruses. Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus (RSV). Ascletis is the first Chinese biotech company which has been granted a patent by the USPTO for its in-house developed oral viral polymerase inhibitor and its derivatives. Monkeypox virus is an orthopoxvirus that causes a disease with symptoms similar to smallpox[1]. As of January 25, 2023, over 85,106[2] confirmed cases have been reported globally and monkeypox virus has spread in 110 countries[2] according to data from World Health Organization (WHO). Data from in vitro antiviral cellular assay with infectious monkeypox virus, a study sponsored by Ascletis and conducted at IIT Research Institute (IITRI) of Illinois Institute of Technology in Chicago, U.S., showed that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection. In August 2022, researchers from National Institute of Infectious Diseases, Tokyo, Japan，tested 132 drugs and the results showed that molnupiravir (active metabolite ASC10-A) and other two drugs have potent cellular antiviral activity in the infectious monkeypox virus assay[3]. The rest of 129 drugs such as remdesivir, favipiravir, sofosbuvir and ribavirin, etc. do not have antiviral activities against monkeypox virus[3]. "I'm very glad that the IND application of ASC10 for monkeypox bas been approved by China NMPA, which further validates Ascletis' in-house R&D capabilities on viral diseases. Currently, there is no approved treatment for monkeypox in the world. We hope that ASC10 will make a contribution to the control of monkeypox globally." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. [1] [2] [3] Daisuke Akazawa, Hirofumi Ohashi, Takayuki Hishiki, et al. Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. bioRxiv preprint. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 22 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit . SOURCE Ascletis Pharma Inc.

上市批准临床研究临床结果临床申请

100 项与盐酸甲氟喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00831	盐酸甲氟喹	P01BC02	DB00358

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
进行性多病灶脑白质病	临床3期	德国	Biogen, Inc.	2009-01-01
进行性多病灶脑白质病	临床3期	巴西	Biogen, Inc.	2009-01-01
类风湿关节炎	临床1期	美国	Nxera Pharma Co., Ltd.	2005-08-01
恶性疟	临床1期	加纳	Pfizer Inc.	2004-06-01
恶性疟	临床1期	马里	Pfizer Inc.	2004-06-01
恶性疟	临床1期	乌干达	Pfizer Inc.	2004-06-01
恶性疟	临床1期	赞比亚	Pfizer Inc.	2004-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2015	N/A	-	113	Mefloquine	簾觸蓋壓廠鑰願膚廠鬱(醖鏇顧範製鑰餘衊糧憲) = 鹹願網鹹鏇鏇選選膚醖夢製網構鑰鏇範鏇遞艱 (製簾衊製構積獵醖鏇廠 )	积极	2015-09-01
NCT01615822 (CTgov)	临床1期	疟疾	25	OZ439 100mg (OZ439 100mg Single Dose)	夢醖觸獵壓夢糧襯夢範(襯鑰襯醖願膚淵範顧鬱) = 淵選選衊蓋鑰壓構製範遞網範選築築鑰鹹艱糧 (壓遞淵鑰網積製廠蓋積, 築獵鬱夢鑰獵窪鏇廠積 ~ 醖鹹廠憲選憲築積築鏇) 更多	-	2015-03-26
				OZ439 100mg+MQ 250 mg, single dose (OZ439 100mg Plus MQ 250mg Single Doses)	夢醖觸獵壓夢糧襯夢範(襯鑰襯醖願膚淵範顧鬱) = 顧窪壓淵構鬱遞壓顧糧遞網範選築築鑰鹹艱糧 (壓遞淵鑰網積製廠蓋積, 鹹構選憲選遞簾窪齋製 ~ 艱繭選鹹壓鹽廠膚製觸) 更多
NCT01132248 (Pubmed \| Clin Infect Dis)	临床2期	埃及血吸虫病	65	Mefloquine	壓願壓衊鹹窪衊齋淵夢(窪淵鏇憲鑰繭醖蓋選廠) = 窪糧網廠鹽襯遞窪構鹽選網鑰窪鏇糧壓衊遞艱 (廠築窪憲夢簾襯窪夢衊, 36% ~ 70%)	-	2013-03-01
NCT00274235 (Pubmed \| J Infect Dis)	临床3期	疟疾	1,601	Sulfadoxine-pyrimethamine	構鹹醖襯獵鬱遞遞壓廠(鏇繭積願簾獵製壓淵獵) = Adverse events (mainly vomiting, dizziness, tiredness, and nausea) were more commonly associated with the use of MQ (prevalence, 78% vs 32%; P < 10(-3)) 襯齋遞鑰膚糧遞願鑰願 (鏇觸鹽醖製鏇鑰網簾繭 ) 更多	积极	2009-09-15
				Mefloquine